Why AbCellera Biologics Inc.’s (ABCL) Stock Is Down 5.81%
As of Friday, November 20, AbCellera Biologics Inc.’s ABCL share price has dipped by 5.81%, which has investors questioning if this is right time to buy.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,164.9 | $3,333.2 | 62% |
|
| Shares Out (Mil) | 318.1 | 107.2 | 83% |
|
| Institutional Ownership | 59.3% | 88.4% | 38% |
|
| Float (Mil) | 224.5 | 79.2 | 75% |
|
| Beta | 1.59 | 1.15 | 84% |
|
| Avg Daily Volume (000s) | 3,009 | 958 | 86% |
|
| Price Change (52-week) |
168.4% | 81.2% | 99% |
|
| Growth | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (20.3%) | 7.5% | 2% |
|
| Net Income (5yr) | (26.4%) | (12.9%) | 16% |
|
| EPS (5yr) | (25.3%) | 1.4% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.1%) | (15.0%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 10 | 9 | |
| Current EPS | ($0.155) | ($0.609) | ($0.704) | |
| Month Ago EPS | ($0.172) | ($0.674) | ($0.763) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.170) | ($0.656) | ($0.715) | |
| Year/Year Chg | 19.2% | 24.3% | 56.1% | |
| Financials | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $68 | $816 | 22% |
|
| Net Income (TTM) (Mil) | ($148) | ($24) | 8% |
|
| EPS (TTM) | ($0.484) | ($0.300) | 27% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | $79 | 17% |
|
| Net Cash Flow (TTM) (Mil) | $80 | $4 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $128 | $263 | 46% |
|
| Enterprise Value (Q1) (Mil) | $2,969 | $3,667 | 55% |
|
| Valuation | ABCL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.97 | 2.97 | 71% |
|
| P/E | na | 33.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.4 | na |
|
| Ratios | ABCL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (174.5%) | 47.5% | 1% |
|
| Net Margin | (218.6%) | (3.5%) | 4% |
|
| ROA | (10.4%) | (4.5%) | 24% |
|
| ROE | (14.6%) | (3.6%) | 25% |
|
| Liabilities to Assets | 29.2% | 40.9% | 20% |
|
| F-Score | 6 | 5 | 67% |
|
AbCellera Biologics Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors